JREE 📈 JPMorgans (Ireland) ICAV - - Overview
Exchange: XETRA • Country: Germany • Currency: EUR • Type: Etf • ISIN: IE00BF4G7183 • Europe Large-Cap Blend Equity
JREE: European, Stocks, Index, Fund, Equity
‣ Company URL: http://www.jpmorganassetmanagement.com ‣ Domicile: Ireland ‣ Index Name: Morningstar DM Eur TME NR EUR
Additional Sources for JREE ETF
JREE ETF Overview
| Market Cap in USD | 1,279m |
| Category | Europe Large-Cap Blend Equity |
| IPO / Inception | 2020-06-30 |
JREE ETF Ratings
| Growth 5y | 56.6% |
| Fundamental | - |
| Dividend | - |
| Rel. Strength Industry | 131 |
| Analysts | - |
| Fair Price Momentum | 38.33 EUR |
| Fair Price DCF | - |
JREE Dividends
No Dividends PaidJREE Growth Ratios
| Growth Correlation 3m | -60.7% |
| Growth Correlation 12m | 50.1% |
| Growth Correlation 5y | 91.6% |
| CAGR 5y | 6.73% |
| CAGR/Mean DD 5y | 1.15 |
| Sharpe Ratio 12m | 0.30 |
| Alpha | -12.24 |
| Beta | 0.66 |
| Volatility | 17.48% |
| Current Volume | 4.4k |
| Average Volume 20d | 11.8k |
What is the price of JREE stocks?
As of December 27, 2024, the stock is trading at EUR 41.76 with a total of 4,385 shares traded.
Over the past week, the price has changed by -0.78%, over one month by -0.19%, over three months by -5.13% and over the past year by +6.97%.
As of December 27, 2024, the stock is trading at EUR 41.76 with a total of 4,385 shares traded.
Over the past week, the price has changed by -0.78%, over one month by -0.19%, over three months by -5.13% and over the past year by +6.97%.
Is JPMorgans (Ireland) ICAV - a good stock to buy?
Partly, yes. Based on ValueRay Analyses, JPMorgans (Ireland) ICAV - (XETRA:JREE) is currently (December 2024) ok to buy, but has to be watched. It has a Growth Technical Rating of 56.57 and therefor an somewhat technical positive rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of JREE as of December 2024 is 38.33. This means that JREE is currently overvalued and has a potential downside of -8.21%.
Partly, yes. Based on ValueRay Analyses, JPMorgans (Ireland) ICAV - (XETRA:JREE) is currently (December 2024) ok to buy, but has to be watched. It has a Growth Technical Rating of 56.57 and therefor an somewhat technical positive rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of JREE as of December 2024 is 38.33. This means that JREE is currently overvalued and has a potential downside of -8.21%.
Is JREE a buy, sell or hold?
JPMorgans (Ireland) ICAV - has no consensus analysts rating.
JPMorgans (Ireland) ICAV - has no consensus analysts rating.
What are the forecast for JREE stock price target?
According to ValueRays Forecast Model, JREE JPMorgans (Ireland) ICAV - will be worth about 42.2 in December 2025. The stock is currently trading at 41.76. This means that the stock has a potential upside of +0.96%.
According to ValueRays Forecast Model, JREE JPMorgans (Ireland) ICAV - will be worth about 42.2 in December 2025. The stock is currently trading at 41.76. This means that the stock has a potential upside of +0.96%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 42.2 | 1% |